triamcinolone + moxifloxacin

Triamcinolone + moxifloxacin is a fixed-dose combination of two active pharmaceutical ingredients: triamcinolone acetonide, a synthetic corticosteroid with potent anti-inflammatory properties, and moxifloxacin, a fourth-generation fluoroquinolone antibiotic. This combination is primarily administered via intraocular (intravitreal or transzonular) injection at the time of cataract surgery to control postoperative inflammation and prevent infection. The corticosteroid component (triamcinolone) acts by inhibiting multiple inflammatory cytokines and suppressing leukocyte infiltration, while the antibiotic component (moxifloxacin) inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial replication. The product is used as an alternative to topical eyedrop regimens for patients undergoing ocular surgery, especially those who may have difficulty adhering to postoperative drop schedules[1][6][8]. Some compounded formulations may include additional excipients such as poloxamer 407[2].

Brand names

Tri-Moxi+ PF

Other names

triamcinolone acetonide + moxifloxacinTriamcinolone-moxifloxacin ophthalmic preparation